Drug Profile
EYS 609
Alternative Names: EYS-609Latest Information Update: 06 Mar 2024
Price :
$50
*
At a glance
- Originator Eyevensys
- Developer PulseSight Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Choroidal neovascularisation; Diabetic macular oedema; Retinal vein occlusion; Wet age-related macular degeneration
Most Recent Events
- 15 Sep 2023 Discontinued - Preclinical for Choroidal neovascularisation in France (Intraocular)
- 15 Sep 2023 Discontinued - Preclinical for Diabetic macular oedema in France (Intraocular)
- 15 Sep 2023 Discontinued - Preclinical for Retinal vein occlusion in France (Intraocular)